Universal Beteiligungs und Servicegesellschaft mbH Has $1.04 Million Holdings in Pacific Biosciences of California, Inc. $PACB

Universal Beteiligungs und Servicegesellschaft mbH raised its holdings in Pacific Biosciences of California, Inc. (NASDAQ:PACB) by 97.9% during the third quarter, HoldingsChannel.com reports. The fund owned 808,700 shares of the biotechnology company’s stock after purchasing an additional 400,000 shares during the period. Universal Beteiligungs und Servicegesellschaft mbH’s holdings in Pacific Biosciences of California were worth $1,035,000 at the end of the most recent reporting period.

Several other institutional investors have also recently bought and sold shares of the business. Cim Investment Management Inc. boosted its stake in shares of Pacific Biosciences of California by 100.7% in the 2nd quarter. Cim Investment Management Inc. now owns 25,550 shares of the biotechnology company’s stock valued at $32,000 after purchasing an additional 12,822 shares in the last quarter. Wealth Enhancement Advisory Services LLC increased its position in Pacific Biosciences of California by 47.8% during the 2nd quarter. Wealth Enhancement Advisory Services LLC now owns 30,113 shares of the biotechnology company’s stock worth $37,000 after purchasing an additional 9,739 shares in the last quarter. SteelPeak Wealth LLC lifted its stake in Pacific Biosciences of California by 95.6% in the 3rd quarter. SteelPeak Wealth LLC now owns 29,930 shares of the biotechnology company’s stock valued at $38,000 after purchasing an additional 14,626 shares during the last quarter. Prudential Financial Inc. boosted its position in Pacific Biosciences of California by 73.0% in the second quarter. Prudential Financial Inc. now owns 35,684 shares of the biotechnology company’s stock valued at $44,000 after buying an additional 15,062 shares in the last quarter. Finally, Financial Advocates Investment Management bought a new stake in shares of Pacific Biosciences of California during the second quarter worth $50,000.

Wall Street Analyst Weigh In

A number of research analysts have recently commented on the company. Weiss Ratings reiterated a “sell (e+)” rating on shares of Pacific Biosciences of California in a research note on Thursday, January 22nd. Stephens upped their target price on Pacific Biosciences of California from $1.80 to $2.00 and gave the stock an “overweight” rating in a report on Monday, November 10th. Barclays increased their target price on Pacific Biosciences of California from $1.50 to $2.00 and gave the company an “equal weight” rating in a research report on Monday, December 15th. Finally, Piper Sandler boosted their price target on Pacific Biosciences of California from $1.50 to $2.00 and gave the stock a “neutral” rating in a report on Tuesday, November 11th. Three equities research analysts have rated the stock with a Buy rating, three have given a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, the stock currently has a consensus rating of “Hold” and a consensus price target of $2.08.

Pacific Biosciences of California Price Performance

Shares of PACB opened at $2.26 on Friday. The business has a 50-day moving average of $2.18 and a 200-day moving average of $1.75. The company has a debt-to-equity ratio of 17.88, a current ratio of 6.24 and a quick ratio of 5.40. The company has a market capitalization of $682.32 million, a price-to-earnings ratio of -1.03 and a beta of 2.20. Pacific Biosciences of California, Inc. has a 1 year low of $0.85 and a 1 year high of $2.73.

Pacific Biosciences of California (NASDAQ:PACB) last released its earnings results on Wednesday, November 5th. The biotechnology company reported ($0.12) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.16) by $0.04. Pacific Biosciences of California had a negative net margin of 325.02% and a negative return on equity of 101.49%. The business had revenue of $38.44 million during the quarter, compared to the consensus estimate of $40.25 million. As a group, equities research analysts anticipate that Pacific Biosciences of California, Inc. will post -0.72 earnings per share for the current year.

Pacific Biosciences of California Company Profile

Pacific Biosciences of California, Inc develops, manufactures and sells high-performance DNA sequencing systems for genetic and genomic analysis. The company’s proprietary single-molecule, real-time (SMRT) sequencing technology is designed to enable long-read sequencing, offering high accuracy for applications such as de novo genome assembly, transcriptome characterization and structural variation analysis. Pacific Biosciences markets a suite of instruments, including the Sequel and Sequel IIe systems, alongside reagents, consumables and data analysis software to support a range of life science research.

Founded in 2004 and headquartered in Menlo Park, California, Pacific Biosciences has expanded its global reach by serving academic institutions, biotechnology and pharmaceutical companies, and government research centers across North America, Europe and Asia.